TMTC3

Across TCGA pan-cancer cohorts, TMTC3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMTC3 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMTC3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMTC3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where TMTC3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.989	0.844	.003	38	view →
PDAC	DFS	Quartile	All	0.647	0.880	.001	30	view →
LUAD	DFS	Median	III,IV	0.728	0.283	.006	20	view →
LSCC	DFS	Tertile	All	1.000	0.918	.019	7	view →
CCRCC	DFS	Median	IV	0.382	0.932	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMTC3–HNSC (DFS)

Open the HNSC breakdown →